Why Smith & Nephew (SNN) Deserves a Spot Among the UK’s Safest Dividend Stocks

Smith & Nephew plc (NYSE:SNN) is included among the Top 10 Safest Dividend Stocks in the UK.

Why Smith & Nephew (SNN) Deserves a Spot Among the UK’s Safest Dividend Stocks

A healthcare professional putting the finishing touches on a patient’s knee implant in an operating theater.

Smith & Nephew plc (NYSE:SNN), a global medical technology company based in the UK, provides a broad selection of products and services in the medical equipment sector to meet the needs of its customers.

In its Q1 2025 earnings, Smith & Nephew plc (NYSE:SNN) reported a strong start to the year, attributing growth across its portfolio to progress made under its 12-Point Plan for operational improvements. Core platforms, including CORI, EVOS, REGENETEN, and the company’s Negative Pressure Wound Therapy offerings, saw robust double-digit growth during the quarter. The company also continued its rapid pace of innovation, with additional product launches planned for the year. While challenges from the Chinese market persisted, management believes the worst of their impact has likely passed.

Smith & Nephew plc (NYSE:SNN) has a progressive dividend policy and has paid regular dividends to shareholders since 1937. The company currently offers a semi-annual dividend of $0.288 per share for a dividend yield of 2.37%, as of July 25. It is one of the best FTSE dividend stocks to invest in.

While we acknowledge the potential of SNN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SNN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 14 Stocks That Paid Special Dividends in 2025 and Dividend Champions vs Aristocrats: 12 Under-the-Radar Stocks to Buy

Disclosure: None.